[1] Owens B,BriscoeGV B .1995 .Coupling between gamma irradiation,p53 induction and the apoptotic response depends upon cell type in vivo. JCeiiSci, 108 : 1841-3.
[2] Hupp TR,Migley GA . .The p53 responseto ionizing radiationin adult and developing murinetissues. Oncogen, 2757 : .
[3] Cook MG .1999 .RichesAC, eta! p53 mutations in tumors derived from irradiatedhuman thyroid epithelial cells. MutatRes, 425(2) : 231-8.
[4] .1999 .The involvement of p53 in dopamine-induced apoptosis of cerebellargranule neurons and leukemic cells overexpressingp53. Cell MoiNeurobioi, 19(2) : 261-76.
[5] Roth JA,NemunaitisJ JA .1999 .Adenovirusmediated p53 gene transferin advanced non-small cell lung cancer. JNat!Cancerinst, 91(9) : 763-771.
[6] .1999 .Flow cytometricdetection of p53 proteinafterincubation of a pre-B cell line with antitumor agents. Cytometry, 35(3) : 267-73.
[7] .1999 .. AnnOncot, 10(2) : 139-150.
[8] Krogh JM .1998 .Primarycentral nervouslymphomas in immunocompetent individuals: Epstein-Barrvirus genome, Ki-67 proliferativeindex, p53 and bcl-2 gene expression. Leuk Lymph, 30(1-2) : 313-142.
[9] Han AC .1998 .Adenocarci noma arising in extragonadal endometriosis; an immunohistochemical study. Cancer, 83(6) : 1163-9.
[10] .1998 .! Expression of proliferatingcell nuclearantigen (PCNA) and p53, bcl-2 of c-erbB-2 proteins on Reed-Sternberg Cells: prognostic significance in Hodgkin's disease. Neopiasma, 45(3) : 140-7.
[11] .1999 .Altered patternsof retinoblastomagene productexpressionin benign, pre-malignantand malignant epithelium of the larynx: an immunohistochemical study including correlationwith p53, bcl-2 and proliferatingindices. AnticancRes, 19(1 A)) : 541-5.
[12] Cosmi EV .1997 .;17(1. AnticancRes, : 401-5.
[13] .1998 .Prognostic importanceof p53 and c-erbB-2 oncoprotein overexpressionin patients with breastcancer. JMedAssoc Thai, 81(9) : 698-704.
[14] Bebenek M .1999 .BarJK, HarlozinsAk, et ai Prospective studies of P53 and c-erbB-2expressionin relationship to clinicopathological parametersof human ductal breastcancerin the second stage of clinical advancement. Anticanc Res, 18 : 619-23.
[15] .1996 .The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. JNat!Cane inst, -88 : 173-T82.
[16] .1999 .K-ras gene mutations correlatewith tumoraggressiveness but are not of routine prognostic value in colorectal cancer. JCtinOncoi, 17(5) : 1375-81.
[17] .1995 .The p53 tumorsuppressorgene and tumor prognosis: is there any relationship. J Pathol, 177 : 221-4.
[18] Lowe SW .1993 .-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cells, 74 : 957-67.
[19] Lowe SW .1994 .BodiesS, McClatcheAy, etal p53 status and the efficacy of cancer therapy in vivo. Science, 266 : 807-810.
[20] .1994 .The clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cane Res, 54 : 2914-8.
[21] Lo GY,Lam KY,Wan KY .1999 .Anaplastic carcinomaof the thyroid. AmJSurg, 177(4) : 337-339.
[22] Aoyagi M .1999 .YamamotM, eta! p53 overexpression and proliferativepotential in malignant meningiomas. Acta Nuerochir Wien, 14(1) : 53-61.
[23] .1999 .Numericalchromosomal aberrationsin muscle invasive squamous cell and transitional cell cancer of the urinarybladder; an alternative to classic prognostic indicator?. Urology, 53(5) : 1005-10.
[24] Adachi J,Ookawa K,Kohno T .1998 .of small cell lung carcinoma induced by different levels of wild-type p53 expression. Cell Death Differ, 5(2) : 148-55.
[25] .1999 .Lung cancer and past occupational exposureto asbestos. Role of p53 and K-ras Mutations. Am J Respir Cell Mo! Bio!, 5(4) : 667-74.
[26] Yao T .1999 .Minute gastriccarcinoma of different type with special referenceto the significance of intestinal metaplasia, proliferativezone and p53 protein during tumor development. Cancer, 85(8) : 1719-29.
[27] .1996 .Immunohistochemical evaluation of p53 oncoprotein in transitional cell carcinoma of the upper urinarytract. Hum Pathol, 27 : 1336-40.
[28] .1999 .. Jdin Oncol, 17(5) : 1382-1390.
[29] Igawa M . .ShigenoK eta! Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferationand apoptosis. Oncology1999, 56(3) : 239-247.
[30] .1999 .The expression of proliferatingcell nuclearantigen (PCNA) and p53 protein correlatewith prognosisof patients with oral squamous cell crcinoma. Fukuoka IgakuZasshi, 90(1) : 6-13.
[31] Oga A,A A .1999 .Chromosome 17 abnormalitiesin squamous cell carcinomaof the oral cavity and its relationshipwith p53 and bcl-2 expression. Anticancer Res, 19 : 81-86.
[32] .1997 .A new prognostic markerforhead and neck Cancer-p53serumantibodies. Anficancer, 17 : 4175.
[33] .1997 .Determinationof the oncogenses p53 and cerbB2in the tumorcytosols of advanced hepatocellular carcinoma [HCC] and correlationto survival time. Anticancer, 17(6C) : 4178.
[34] .1997 .A comparativestudy of p53 expressionand p53 mutations in effusion cells of patients with ovarian carcinoma. Relation to response for chemotherapy. Anticancer, 17(6C) : 4188.
[35] Yano M,Dohi K .1999 .451 expressionof the proliferatingantigen Ki67, PCNA and. JeziorskiA and Olborski B: The, 14(3) : 447.
[36] . .: sion: a population-based endometrial carcinoma 503-10. JExp din Cane Res, 17(4) : .